Paul Sekhri

The next big biotech su­per­star? Paul Sekhri has some thoughts on that

It oc­ca­sion­al­ly oc­curs to Paul Sekhri that if they pull this off, his com­pa­ny will be on the front page of the New York Times and a lead sto­ry in just about every ma­jor news out­let on the plan­et. He tries not to dwell on it, though.

“I just want to be laser-fo­cused on get­ting to that point,” Sekhri says, be­fore ac­knowl­edg­ing, “Yes, it ab­solute­ly crossed my mind.”

Sekhri, a long­time bio­phar­ma ex­ec­u­tive with tenures at Sanofi and No­var­tis, is now en­ter­ing year three as CEO of eGe­n­e­sis, the biotech that George Church pro­tégé Luhan Yang found­ed to ge­net­i­cal­ly al­ter pigs so that they can be used for or­gan trans­plants. He led them through one megaround and has just closed an­oth­er, rais­ing $125 mil­lion from 17 dif­fer­ent in­vestors to push the first-ever (hu­man­ized) pig to hu­man trans­plants in­to the clin­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.